Oncternal Therapeutics Analyst Ratings
HC Wainwright & Co. : Oncemic Therapeutics (ONCT.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $28.00 to $19.00.
Oppenheimer Reaffirms Their Hold Rating on Oncternal Therapeutics (ONCT)
HC Wainwright & Co. : Oncemic Therapeutics (ONCT.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $30.00 to $28.00.
Oncternal Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Joint (JYNT), Xtant Medical Holdings (XTNT) and Oncternal Therapeutics (ONCT)
Oppenheimer Remains a Hold on Oncternal Therapeutics (ONCT)
Oncternal Therapeutics Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Coherus Biosciences (CHRS), Oncternal Therapeutics (ONCT)
HC Wainwright & Co. Reiterates Buy on Oncternal Therapeutics, Maintains $2 Price Target
Oncternal Therapeutics Analyst Ratings
Brookline Capital Upgrades Oncternal Therapeutics to Buy, Announces $2 Price Target
Oncternal Therapeutics Analyst Ratings
Buy Rating for Oncternal Therapeutics: Promising Clinical Programs and Potential Catalysts
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Oncternal Therapeutics (ONCT) and Ventyx Biosciences (VTYX)
HC Wainwright & Co. Upgrades Oncternal Therapeutics to Buy, Announces $2 Price Target
Oncternal Therapeutics Analyst Ratings
Cantor Fitzgerald Reiterates Neutral on Oncternal Therapeutics, Maintains $1.3 Price Target
Oncternal Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Oncternal Therapeutics (ONCT), Adagene (ADAG) and Omega Therapeutics (OMGA)
No Data